Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : VVUS: VIVUS INC. (NASDAQ) -- Ignore unavailable to you. Want to Upgrade?

To: VLAD who wrote (21499)	4/28/1999 7:16:00 PM
From: Amots	Read Replies (1) \| Respond to of 23519

VLAD. Have a good trip. I'll be out all next week, so I'll just leave GTC to sell 1/2 position at 18. -g- Amots

To: VLAD who wrote (21499)	4/28/1999 8:28:00 PM
From: Mkilloran	Respond to of 23519

Vlad....Ed marketplace ...look for VVUS to capture 15% or more of the pie over this time period in the attached article with Muse/Alibra: Target market is Viagra failures, cardiac risk patients that want a safer alternative to Viagra, NTG patients that can not use Viagra, patients using other medications that conflict with Viagra, etc #reply-9187367 Now look for VVUS to capture a much larger portion of the Female SD marketplace. Vivus will not have the same issues to deal with in promoting a local solution with a cream/gel for Female SD like the do with MUSE/Alibra in the male population.